KZA Media Thread, page-987

I asked about the change from partnering early for Phase 3 and ownership of paxalisib. I very much liked his response! Keeping the asset longer term as value increases and it would be sensible that Kazia would retain some ownership due to the knowledge we have and will continue to build...

We are now in a far stronger position and are NOT reliant on any large pharma to take this through to registration. I can only imagine what this asset could be worth with all of our trials and others no doubt added as we go through this GBM Agile registration trial!!

He was extremely comfortable, confident and cool...